New Singapore Rules Will Impact Drug Licensing, Trials, Surveillance
This article was originally published in PharmAsia News
Pharmaceutical companies doing business in Singapore are being advised to review the procedures they have in place relating to drug licensing, conducting clinical trials and responding to post-market surveillance in light of proposed legislative changes in the country.
You may also be interested in...
The European Medicines Agency has provided an update on the status of its review of Gilead’s investigational antiviral in the treatment of COVID-19.
Applications to market Roche’s spinal muscular atrophy drug have already been submitted in eight countries including the US, where a decision is due in August.
Hot on the heels of recommending Roche’s drug for triple negative breast cancer, HTA body NICE today said the product should also be used for the first-line treatment of extensive-stage small-cell lung cancer.